New regimen for treatment of irritable bowel syndrome with emphasis on Sulpride as the sole maintenance therapy

Kamel El-Reshaid *, Shaikha Al-Bader **

*Department of Medicine, Faculty of Medicine, Kuwait University, P O Box 24923, 13110 Safat, Kuwait
** Department of Medicine, Nephrology Unit, Amiri hospital, Ministry of health, Kuwait

ABSTRACT

The efficiency and safety of Sulpirid (50 mg twice/daily) was assessed in 563 adult patients with 6 groups of patients with irritable bowel syndrome (IBS) who had failed dietary therapy. The groups included: patients without previous treatment (n: 137), patients who had received a muscarinic antagonists (n: 65), an anticholinergic/benzodiazepine combination (n: 187), a tricyclic antidepressants (n: 62), a selective serotonin reuptake inhibitors (SSRIs) (n: 48) and an antiflatulent (n: 64). Patients were assessed for 6 weeks. Sulpirid was effective and safe in relieving the abdominalgia, anxiety, depression and bowel function. The overall success of Sulpride in treatment of IBS was 84%. Most patients who had failed muscarinic antagonists, antiflatulent and tricyclic antidepressants had > 95% improvement with Sulpride. The success was 88% in those who did not receive prior therapy while it was just 77% and 72% in those who had failed SSRIs and anticholinergic/benzodiazepine combination. In treatment-failures, a further 9.8% improvement was achieved with addition of a SSRI (Escitalopram) and an extra 3.4% with subsequent increase in Sulpride dose to 100 mg X 2 limiting failures to only 2.3%. Tolerance of treatment was good and side-effects developed in 11% patients. In conclusion: Sulpride is an effective and safe drug in IBS.

Keywords: Antidepressants, anxiolytics, irritable bowel syndrome, treatment, Sulpride

INTRODUCTION

Irritable bowel syndrome (IBS) is a chronic alteration of colon function. Invasive gastrointestinal (GI) diagnostics are often unrevealing and hence its etiology has been considered a functional one [1]. According to its main presentation, it has been classified into diarrhea-predominant, constipation-predominant, and enterospasmodic disorders [2]. IBS is a common disorder affecting 10 to 15% of people in the developed world [3]. The aggregate cost of irritable bowel syndrome in the United States has been estimated at $1.1–10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7–30 billion [4]. The disorder is usually associated with anxiety, depression and mood disorder. Hence, low dose antidepressant drugs with or without antispasmodics has been used for its treatment [5]. Nortriptyline (Pamelor), a tricyclic antidepressant (TCA) which inhibits the gut nerve-activity, has been used for its enterospastic and diarrheal disorders. On the other side; a selective serotonin reuptake inhibitors (SSRIs) like Zoloft has been used to speed the gut in constipated subjects. Moreover, direct antispasmodics as well as antidiarrheal agents (Loperamide) and laxatives were common additives as well as benzodiazepine for anxiety with risk of addiction. In search for an acceptable treatment for IBS; we elected to evaluate the role of control of anxiety rather than depression in management of IBS. Hence, we conducted this study to evaluate the safety and efficacy of low dose of Sulpride in management of this disorder.

PATIENTS AND METHODS:

The study started from 1st of January 2014 till 31st June 2019. It included all patients who presented with IBS to the Al-Amiri nephrology center. The latter was established at Al-Amiri hospital in 1976 in the center of Kuwait city. It is the referral center for all patients with kidney diseases in the capital area of Kuwait. It has adequate diagnostic and therapeutic facilities to care for both in- and out-patients with renal diseases and all their medical problems. Moreover, it acted also as a tertiary kidney center for all Kuwait.
Inclusion criteria for IBS patients:
Patients were included in the study if they fulfilled Rome IV criteria which include recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with defecation or associated with change in the frequency of defecation or appearance of stool [6].

Exclusion criteria:
1- Patients older than 50 years at start of symptoms or less than 14 years.
2- Those with nocturnal pains and weight loss.
3- Patients with GI reflux disease, peptic disease, Helicobacter infection, coeliac disease (tested by both serological markers and biopsy of second part of duodenum), and inflammatory bowel disease. Moreover, patients with gall stones, gynecological disorders, autoimmune diseases and endocrine abnormalities. Hence all patients had normal: full blood testing, liver function tests, ESR, urine routine and microscopy, stool analysis, ultrasound of the abdomen and pelvis, upper and lower gastrointestinal endoscopy. TSH and Free T4 were done in all patients and tests for other endocrine glands as well as and autoimmune system when indicated.
4- Patients with creatinine clearance < 60 ml/minute.

Study design:
Patients were included in the study if they did not receive prior treatment for IBS as well as those who had had failed previous drug-therapy. All patients had instructions regarding dietary measures that included increasing soluble fiber intake, gluten-free diet and avoidance of fermentable sugars for 6 weeks. Patients who did not improve or had failed other treatments were included in the study. Initially, all patients were treated, exclusively, with Sulpride 50 mg X2 for 6 weeks. Failures were further retested after addition of Escitalopram up to 20 mg at night to Sulpride 50 mg X2 for another 6 weeks. Furthermore, subsequent failures were retested after increasing the dose of Sulpride dose to 100 mg twice/daily in addition to Escitalopram.

Statistical analysis:
Since the age and duration of IBS prior to treatment were not normally distributed: (a) the median and (interquartile range) were used to express the groups and (b) Kruskal-Wallis test was used to compare the difference between groups.

RESULTS
Over the past 4 and 1/2 years, a total of 2371 patients were screened. Symptoms of significant IBS were detected in 577 patients (24%). Fourteen patients lost follow up. The demographic data on the remaining 563 patients are summarized in (Table 1). All patients were adults with a median age of 32[11] and youngest was 18 and eldest was 46 years. Gender distribution was (Female/Male: 1:9). The median of duration of IBS prior to the study was 6(4) years and shortest was 2 and longest was 18 years.

Study population:
A 137 patients did not receive prior treatment for IBS while others had treatment-failure with; Mebeverine HCl (Duspatalin) as a muscarinic antagonists (n: 65), Chloridiazepoxide/clidinium bromide (Librax) as an anticholinergic/benzodiazepine combination (n: 187), Nortriptyline (Pamelor) as a TCA (n: 62), Sertraline (Zoloft) as a SRRI (n: 48) and Simethicone as an antiflatulent (n: 64). There was no statistical difference between the 6 groups with regards age and duration of IBS before entering the study.

Efficacy of 6 weeks of Sulpride:
The overall success of Sulpride in treatment of IBS was 84%. Most patients who had failed muscarinic antagonists, antidepressants and TCAs had improvement with Sulpride (> 95%). The success was also acceptable in those who did not receive prior therapy (88%). However, the success rate was just 77% and 72% in those who had failed SSRI and anticholinergic/benzodiazepine combinations.

Management of the initial non-responders:
An additional 9.8% improvement was achieved with additional of Escitalopram and further 3.4% with increasing Sulpride dose to 100 mg X 2 leaving only 2.3% treatment failure.

Treatment side-effects:
Sulpride produced gynecomastia in 2 males and galactorrhea with amenorrhea in 8 conception-seeking females. It was entered as a treatment failure and the drug was discontinued. The extrapyramidal (Parkinsonian tremors) and anticholinergic side-effects were rarely seen in our adult population. Sedation limited increment of the dose of Escitalopram to > 10 mg daily in 6 patients.

Final treatment failures:
Ten patients could not tolerate Sulpride therapy for side-effects and 3 were true treatment failure.

DISCUSSION
The pathophysiology of IBS is uncertain. Theories include genetic mutations, abnormal GI motility, enhanced gut pain sensation (visceral hypersensitivity, bacterial flora overgrowth and psychological changes [7]. One theory concerning the pathophysiology of IBS involves the neurotransmission between the central nervous system (CNS) and the intestines. Numerous structures in the CNS connect to the gut through serotonergic nerves that help regulate its motility, sensation, and secretion. In patients with IBS, an imbalance in the function of serotonin leads to the deregulation of intestinal motility. Based on this serotonin imbalance theory, various treatment approaches have been suggested [8]. The most widely used antidepressants in IBS are TCAs and SSRIs, as they reduce pain and improve global IBS symptoms. Their analgesic and anxiolytic effect is thought to improve GI motility and function. However, in a recent meta-analysis of multiple studies, nearly half of patients were refractory to both treatments [9, 10]. Local anticholinergic-antispasmodics such as Mebeverine, hyosyamine, dicyclomine and belladonna have been utilized, for short term, relief of abdominal pain. However, common side-effects viz. dry mouth, dizziness, blurry vision, and urinary retention limit their long-term use especially in the elderly [11]. Moreover, major health concerns faced multiple drugs viz. (a) Alosetron, a 5-HT3 receptor antagonist used for treatment of IBS-D due to ischemic colitis (b) Tegaserod, a 5-HT4 receptor agonist, used for treatment of IBS-C due to increased risk of heart attack and stroke (c) Lubiprostone, a chloride channel activator for the management of IBS-C due to pregnancy teratogenicity (d) Linaclootide, a guanylate cyclase (GC-C) agonist and acts locally in the intestine due to concerns in pediatric patients and deaths in young juvenile mice and (e) Loperamide, a widely available OTC product, has shown to reduce GI transit time and improve diarrhea and urgency.
However, it did not improve abdominal pain and global IBS symptoms [11, 12]. Dietary modification included: (a) exclusion of beans, alcohol, caffeine, and fatty meals, and gas-producing foods such as broccoli, legumes, cabbage, and avocado in diet and increase intake of dietary fiber ispaghula/pyllium (e.g. Metamucil) in constipated patients [13]. (b) probiotics, containing Bifidobacterium, to prevent overgrowth of pathogenic GI bacteria in and reduce its triggering local inflammation [14]. (c) Rifaximin, a locally-acting antibiotic used for traveler’s diarrhea and hepatic encephalopathy since bacterial resistance and side effects were a major concern [15], and carminatives (Simithicone) as anti-foaming agent that decrease the surface tension of gas bubbles, causing them to combine into larger bubbles in the gut [16].

In our study, we elected to use a systemic a non-addicting anxiolytic agent since patients with IBS have multiple bodily symptoms (somatization) i.e. not a simple GI disorder [17]. Hence, we elected to use Sulpride. The drug is an atypical antipsychotic medication of the benzamide class. At high-doses, it is being used for treatment of psychosis associated with schizophrenia, major depressive disorders and panic attacks. However, in low-dosage it is an excellent anxiolytic agent. Contrary to benzodiazepines it is not associated with dependence, tolerance, hypoventilation and sleepiness [18]. It is a selective antagonist at dopamine D2, D3 and 5-HT1A receptors. Antagonism at 5-HT1A dominates in doses exceeding 600 mg daily. In low doses, 50–20 mg daily, its prominent feature is antagonism of presynaptic inhibitory dopamine and serotonin receptor, accounting for some antidepressant activity as well as stimulatory effect [19]. Moreover, its beneficial effects include: activation of the endogenous gamma-hydroxybutyrate receptor in vivo at therapeutic concentrations, their upregulation in animal studies and activation of their DNA demethylation in the brain [19-21]. The drug was well tolerated and produced few side-effects (10%). Hyperprolactinemia, leading to gynecomastia in males and galactorrhea with amenorrhea in conception-seeking females limited its use. Moreover, its extrapyramidal (Parkinsonian tremors) and anticholinergic side-effects were rarely seen at our adult population [18].

To improve the rate of success we elected first to add Escolatalopram. The latter is a SSRI with limited anticholinergic side-effects yet with potent anti-somatiform effect [22]. Finally, patients who did not respond to Sulpride- Escolatalopram combination had to be treated with higher dosage of Sulpride and it further improved the success rate. In our study, we elected to avoid high-maintenance dosage of Sulpride to avoid its short and long-term side-effects. In conclusion; Sulpride is a safe and efficacious agent in management of IBS.

REFERENCES:
### Table 1. Showing the results of Sulpride treatment in patients with IBS*

<table>
<thead>
<tr>
<th>Group</th>
<th>No.</th>
<th>Age † (years)</th>
<th>Sex</th>
<th>Duration of † (&gt; 3 months)</th>
<th>Previous treatment</th>
<th>Sulpride 50 mg X 2</th>
<th>Further management Sulpride 100 mg X2</th>
<th>Failed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>137</td>
<td>32(12)</td>
<td>43/94</td>
<td>6(4)</td>
<td>None</td>
<td>121 (88%)</td>
<td>16 (15.5%)</td>
<td>3 (2.3%)</td>
</tr>
<tr>
<td>2</td>
<td>65</td>
<td>32(12)</td>
<td>23/42</td>
<td>6(3)</td>
<td>Direct gut antispasmodics **</td>
<td>63 (97%)</td>
<td>2 (1.5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>3</td>
<td>187</td>
<td>32(13)</td>
<td>57/130</td>
<td>6(4)</td>
<td>Anticholinergic+benzodiazepine ***</td>
<td>134 (72%)</td>
<td>53 (15.5%)</td>
<td>12 (6%)</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>32(11)</td>
<td>28/34</td>
<td>6(5)</td>
<td>Tricyclic antidepressants □</td>
<td>59 (95%)</td>
<td>3 (1.5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>5</td>
<td>48</td>
<td>34(13)</td>
<td>26/22</td>
<td>6(4)</td>
<td>SSRI □□</td>
<td>37 (77%)</td>
<td>11 (15.5%)</td>
<td>4 (6%)</td>
</tr>
<tr>
<td>6</td>
<td>64</td>
<td>32(11)</td>
<td>18/46</td>
<td>6(4)</td>
<td>Antiflatulents □□□</td>
<td>62 (97%)</td>
<td>2 (1.5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Total</td>
<td>563</td>
<td>32(11)</td>
<td>195/368</td>
<td>6(4)</td>
<td></td>
<td>476 (84.5%)</td>
<td>87 (15.5%)</td>
<td>55 (9.8%)</td>
</tr>
</tbody>
</table>

*Sequential treatment: Sulpride 50 mg X2 for 6 weeks then failures had Escitalopram for additional 6 weeks then failures had increment of Sulpride dose to 100 mg X2 for extra 6 weeks

† Age & duration of IBS are expressed in median(IQR).

** Direct gut antispasmodics (muscarinic antagonist): Duspatalin

*** Anticholinergic+Benzodiazepine: Chlordiazepoxide/clidinium bromide (Librax)

□ Tricyclic antidepressants: Nortriptyline (Pamelor)

□□ Selective serotonin reuptake inhibitors (SSRIs): Sertaline (Zoloft)

□□□ Antiflatulents: Simethicone